New findings presented at the annual scientific meeting of the American Heart Association (AHA) and published in the The New England Journal of Medicine show that prescription-grade niacin may be more effective in lowering cholesterol than the popular cholesterol-lowering drugs Zetia and Vitorin. The 208-patient study—which was funded by Abbott Laboratories, the manufacturer of Niaspan, a prescription-grade niacin product—concluded that Niaspan lowered levels of plaque in patients’ arteries more effectively than its drug counterparts.

From Nutrition Business Journal.